Wedbush Starts Voyager Therapeutics (VYGR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Chardan Capital Markets Starts Voyager Therapeutics (VYGR) at Sell
December 9, 2015 9:55 AM ESTChardan Capital Markets initiated coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Sell rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.
Shares of Voyager Therapeutics closed at $30.11 yesterday.
... MorePiper Jaffray Starts Voyager Therapeutics (VYGR) at Overweight
December 7, 2015 6:35 AM ESTPiper Jaffray initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Overweight rating and a price target of $47.00.
Analyst Joshua E. Schimmer commented, "We are initiating coverage of VYGR with an OW rating and $47 PT based on a DCF analysis through 2022 with an 11%... More
Cowen Starts Voyager Therapeutics (VYGR) at Outperform
December 7, 2015 6:30 AM ESTCowen initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Outperform rating.
Analyst Phil Nadeau commented, "Voyagers lead program is VY-AADC01 for the treatment of advanced Parkinsons disease which is on track to produce proof-of-concept data in 2016. We estimate that VY-AADC01... More
